The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent.
The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent.